The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

It's well known that spaceflight causes muscle atrophy and other biological changes in reduced gravity, and especially in ...

Parents have said new screening tests for Spinal muscular atrophy are a "game-changer".

Scotland becomes first part of UK to screen babies for rare muscle disease - All parents will now be offered spinal muscular ...

Researchers discovered that R. inulinivorans plays an important role in muscle strength and could act as a probiotic ...

That’s exactly what a study published today in Science Advances sought to do. The researchers exposed mice aboard the ISS to ...

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing ...

Discussions of cognitive offloading often miss a critical distinction: What AI does to a 45-year-old's brain is categorically ...

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and motor function in a key study.

Researchers found that GLP-1 medicines caused weight loss mainly through fat reduction, with only modest decreases in absolute muscle mass and no disproportionate loss of muscle function. In mice, ...

For most people, spring and summer means fun in the sun. For this 24-year-old, it means avoiding her life-threatening sun allergy.